Evolus Inc Stock Today
| EOLS Stock | USD 12.05 0.16 1.35% |
Performance0 of 100
| Odds Of DistressLess than 45
|
Evolus is selling for under 12.05 as of the 16th of April 2024; that is 1.35 percent increase since the beginning of the trading day. The stock's lowest day price was 11.72. Evolus has 45 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Evolus Inc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 17th of March 2024 and ending today, the 16th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of February 2018 | Category Healthcare | Classification Health Care |
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company was incorporated in 2012 and is headquartered in Newport Beach, California. Evolus operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 61.5 M outstanding shares of which 4.65 M shares are currently shorted by private and institutional investors with about 6.46 trading days to cover. More on Evolus Inc
Moving against Evolus Stock
| 0.85 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
| 0.63 | BNR | Burning Rock BiotechLtd Financial Report 4th of June 2024 | PairCorr |
| 0.52 | NVS | Novartis AG ADR Earnings Call This Week | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
Evolus Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Evolus' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Evolus or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Murthy Simhambhatla | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Health Care, NASDAQ Composite, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Evolus report their recommendations after researching Evolus' financial statements, talking to executives and customers, or listening in on Evolus' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Evolus Inc. The Evolus consensus assessment is calculated by taking the average forecast from all of the analysts covering Evolus. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Evolus' liquidity, profitability, solvency, and operating efficiency, Evolus Inc may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. Financial strength of Evolus Inc is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evolus' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Evolus' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Evolus' financial leverage. It provides some insight into what part of Evolus' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evolus Inc (EOLS) is traded on NASDAQ Exchange in USA. It is located in 520 Newport Center Drive, Newport Beach, CA, United States, 92660 and employs 273 people. Evolus is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 731.21 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Evolus's market, we take the total number of its shares issued and multiply it by Evolus's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Evolus Inc conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 61.5 M outstanding shares of which 4.65 M shares are currently shorted by private and institutional investors with about 6.46 trading days to cover.
Evolus Inc currently holds about 84.48 M in cash with (34.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.51.
Check Evolus Probability Of Bankruptcy
Ownership AllocationEvolus Inc retains a total of 61.5 Million outstanding shares. The majority of Evolus Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Evolus Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Evolus. Please pay attention to any change in the institutional holdings of Evolus Inc as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Evolus Ownership Details
Evolus Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Evolus jumping above the current price in 90 days from now is about 87.12%. The Evolus Inc probability density function shows the probability of Evolus stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.1551 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Evolus will likely underperform. Additionally, evolus Inc has an alpha of 0.1521, implying that it can generate a 0.15 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Evolus to move above the current price in 90 days from now is about 87.12 (This Evolus Inc probability density function shows the probability of Evolus Stock to fall within a particular range of prices over 90 days) .
Evolus Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Evolus that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Evolus' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Evolus' value.| Instituion | Recorded On | Shares | |
| State Street Corporation | 2023-12-31 | 1 M | |
| Millennium Management Llc | 2023-12-31 | 1 M | |
| Geode Capital Management, Llc | 2023-12-31 | 934.3 K | |
| Nuveen Asset Management, Llc | 2023-12-31 | 922.9 K | |
| Rice Hall James & Associates, Llc | 2023-12-31 | 906.2 K | |
| Boothbay Fund Management, Llc | 2023-12-31 | 836.9 K | |
| Ubs Group Ag | 2023-12-31 | 666.3 K | |
| Awh Capital, L.p. | 2023-12-31 | 629.2 K | |
| Marshall Wace Asset Management Ltd | 2023-12-31 | 553.5 K | |
| Nantahala Capital Management, Llc | 2023-12-31 | 5.8 M | |
| Stonepine Capital Management Llc | 2023-12-31 | 5.3 M |
Evolus Historical Income Statement
Evolus Inc Income Statement is one of the three primary financial statements used for reporting Evolus's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Evolus Inc revenue and expense. Evolus Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Evolus' Non Operating Income Net Other is comparatively stable compared to the past year. View More FundamentalsEvolus Stock Against Markets
Picking the right benchmark for Evolus stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Evolus stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Evolus is critical whether you are bullish or bearish towards Evolus Inc at a given time. Please also check how Evolus' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Evolus without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Diagnostics Now
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings |
| All Next | Launch Module |
Evolus Corporate Directors
Evolus corporate directors refer to members of an Evolus board of directors. The board of directors generally takes responsibility for the Evolus' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Evolus' board members must vote for the resolution. The Evolus board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Karah Parschauer | Director | Profile | |
| Kristine Romine | Independent Director | Profile | |
| Peter Farrell | Director | Profile | |
| Robert Hayman | Independent Director | Profile |
How to buy Evolus Stock?
Before investing in Evolus, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Evolus. To buy Evolus stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Evolus. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Evolus stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Evolus Inc stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Evolus Inc stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Evolus Inc, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Evolus Stock please use our How to Invest in Evolus guide.
Already Invested in Evolus Inc?
The danger of trading Evolus Inc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Evolus is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Evolus. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Evolus Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Evolus Inc is a strong investment it is important to analyze Evolus' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Evolus' future performance. For an informed investment choice regarding Evolus Stock, refer to the following important reports: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolus Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Evolus Stock analysis
When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Stocks Directory Find actively traded stocks across global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities |
Is Evolus' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evolus. If investors know Evolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evolus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Revenue Per Share 3.55 | Quarterly Revenue Growth 0.398 | Return On Assets (0.12) | Return On Equity (12.79) |
The market value of Evolus Inc is measured differently than its book value, which is the value of Evolus that is recorded on the company's balance sheet. Investors also form their own opinion of Evolus' value that differs from its market value or its book value, called intrinsic value, which is Evolus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evolus' market value can be influenced by many factors that don't directly affect Evolus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evolus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Evolus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evolus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.